Affordable Growth. Analyze the stocks which are showing good growth, decent profitability and health and are not overvalued from a fundamental perspective.


HARMONY BIOSCIENCES HOLDINGS

Nasdaq / Health Care / Pharmaceuticals

Fundamental Rating

8

Overall HRMY gets a fundamental rating of 8 out of 10. We evaluated HRMY against 198 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making HRMY a very profitable company, without any liquidiy or solvency issues. HRMY is evaluated to be cheap and growing strongly. This does not happen too often! With these ratings, HRMY could be worth investigating further for value and growth and quality investing!.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

In the past year HRMY was profitable.
HRMY had a positive operating cash flow in the past year.
HRMY had positive earnings in 4 of the past 5 years.
Of the past 5 years HRMY 4 years had a positive operating cash flow.
HRMY Yearly Net Income VS EBIT VS OCF VS FCFHRMY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

Looking at the Return On Assets, with a value of 14.56%, HRMY belongs to the top of the industry, outperforming 95.96% of the companies in the same industry.
HRMY's Return On Equity of 22.07% is amongst the best of the industry. HRMY outperforms 92.93% of its industry peers.
HRMY's Return On Invested Capital of 18.94% is amongst the best of the industry. HRMY outperforms 93.43% of its industry peers.
HRMY had an Average Return On Invested Capital over the past 3 years of 18.27%. This is significantly below the industry average of 41.61%.
The 3 year average ROIC (18.27%) for HRMY is below the current ROIC(18.94%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 14.56%
ROE 22.07%
ROIC 18.94%
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
HRMY Yearly ROA, ROE, ROICHRMY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

HRMY has a Profit Margin of 20.36%. This is amongst the best in the industry. HRMY outperforms 92.42% of its industry peers.
In the last couple of years the Profit Margin of HRMY has grown nicely.
Looking at the Operating Margin, with a value of 29.09%, HRMY belongs to the top of the industry, outperforming 93.43% of the companies in the same industry.
In the last couple of years the Operating Margin of HRMY has declined.
The Gross Margin of HRMY (78.06%) is better than 84.34% of its industry peers.
HRMY's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 29.09%
PM (TTM) 20.36%
GM 78.06%
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
HRMY Yearly Profit, Operating, Gross MarginsHRMY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so HRMY is creating value.
The number of shares outstanding for HRMY has been increased compared to 1 year ago.
The number of shares outstanding for HRMY has been reduced compared to 5 years ago.
Compared to 1 year ago, HRMY has an improved debt to assets ratio.
HRMY Yearly Shares OutstandingHRMY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
HRMY Yearly Total Debt VS Total AssetsHRMY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

HRMY has an Altman-Z score of 5.28. This indicates that HRMY is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 5.28, HRMY belongs to the best of the industry, outperforming 82.83% of the companies in the same industry.
The Debt to FCF ratio of HRMY is 0.82, which is an excellent value as it means it would take HRMY, only 0.82 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of HRMY (0.82) is better than 94.95% of its industry peers.
A Debt/Equity ratio of 0.25 indicates that HRMY is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.25, HRMY perfoms like the industry average, outperforming 45.96% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF 0.82
Altman-Z 5.28
ROIC/WACC1.93
WACC9.84%
HRMY Yearly LT Debt VS Equity VS FCFHRMY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

HRMY has a Current Ratio of 3.31. This indicates that HRMY is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.31, HRMY perfoms like the industry average, outperforming 56.57% of the companies in the same industry.
HRMY has a Quick Ratio of 3.27. This indicates that HRMY is financially healthy and has no problem in meeting its short term obligations.
HRMY has a better Quick ratio (3.27) than 60.10% of its industry peers.
Industry RankSector Rank
Current Ratio 3.31
Quick Ratio 3.27
HRMY Yearly Current Assets VS Current LiabilitesHRMY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

9

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 7.82% over the past year.
Measured over the past years, HRMY shows a very strong growth in Earnings Per Share. The EPS has been growing by 44.61% on average per year.
HRMY shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.80%.
Measured over the past years, HRMY shows a very strong growth in Revenue. The Revenue has been growing by 160.13% on average per year.
EPS 1Y (TTM)7.82%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%16.42%
Revenue 1Y (TTM)22.8%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%19.48%

3.2 Future

HRMY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.90% yearly.
Based on estimates for the next years, HRMY will show a very strong growth in Revenue. The Revenue will grow by 21.10% on average per year.
EPS Next Y25.16%
EPS Next 2Y30.64%
EPS Next 3Y31.63%
EPS Next 5Y36.9%
Revenue Next Year17.81%
Revenue Next 2Y18.1%
Revenue Next 3Y18.92%
Revenue Next 5Y21.1%

3.3 Evolution

The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
HRMY Yearly Revenue VS EstimatesHRMY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
HRMY Yearly EPS VS EstimatesHRMY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6 8 10

9

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 12.97, the valuation of HRMY can be described as correct.
87.88% of the companies in the same industry are more expensive than HRMY, based on the Price/Earnings ratio.
HRMY is valuated rather cheaply when we compare the Price/Earnings ratio to 23.99, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 7.93 indicates a rather cheap valuation of HRMY.
Compared to the rest of the industry, the Price/Forward Earnings ratio of HRMY indicates a rather cheap valuation: HRMY is cheaper than 90.40% of the companies listed in the same industry.
HRMY's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 20.35.
Industry RankSector Rank
PE 12.97
Fwd PE 7.93
HRMY Price Earnings VS Forward Price EarningsHRMY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, HRMY is valued cheaply inside the industry as 89.39% of the companies are valued more expensively.
91.41% of the companies in the same industry are more expensive than HRMY, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 8.92
EV/EBITDA 6.97
HRMY Per share dataHRMY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

HRMY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of HRMY may justify a higher PE ratio.
A more expensive valuation may be justified as HRMY's earnings are expected to grow with 31.63% in the coming years.
PEG (NY)0.52
PEG (5Y)N/A
EPS Next 2Y30.64%
EPS Next 3Y31.63%

0

5. Dividend

5.1 Amount

HRMY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A